These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21140241)

  • 21. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
    Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL
    Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
    Le QT; Moon J; Redman M; Williamson SK; Lara PN; Goldberg Z; Gaspar LE; Crowley JJ; Moore DF; Gandara DR
    J Clin Oncol; 2009 Jun; 27(18):3014-9. PubMed ID: 19364954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
    Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.
    Han JY; Lee DH; Lee SY; Park CG; Kim HY; Kim EA; Yoon SM; Lee HG; Lee JS
    Med Oncol; 2005; 22(3):281-90. PubMed ID: 16110139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
    Klautke G; Fähndrich S; Semrau S; Büscher C; Virchow C; Fietkau R
    Lung Cancer; 2006 Aug; 53(2):183-8. PubMed ID: 16757061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
    Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
    J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
    Ichinose Y; Seto T; Sasaki T; Yamanaka T; Okamoto I; Takeda K; Tanaka M; Katakami N; Sawa T; Kudoh S; Saka H; Nishimura Y; Nakagawa K; Fukuoka M
    J Thorac Oncol; 2011 Dec; 6(12):2069-75. PubMed ID: 22052226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
    Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR
    J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
    Sekine I; Harada H; Yamamoto N; Wakabayashi M; Murakami H; Goto K; Nogami N; Seto T; Oshita F; Okamoto H; Tanaka H; Tamura T; Ishikura S; Ohe Y
    Lung Cancer; 2017 Jun; 108():232-237. PubMed ID: 28625642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer.
    Han JY; Kim HT; Lim KY; Yoon SJ; Lee DH; Lee JS
    J Thorac Oncol; 2008 Sep; 3(9):1039-45. PubMed ID: 18758308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: a phase II study.
    Chen LK; Huang H; Liao H; Liu GZ; Zeng YD; Dinglin XX; Xu GC; Wei WD
    Med Oncol; 2012 Sep; 29(3):1687-92. PubMed ID: 21853344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer.
    Sekine I; Sumi M; Satouchi M; Tsujino K; Nishio M; Kozuka T; Niho S; Nihei K; Yamamoto N; Harada H; Ishikura S; Tamura T
    Cancer Sci; 2016 Mar; 107(3):315-9. PubMed ID: 26748638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.
    Xia B; Hong LZ; Cai XW; Zhu ZF; Liu Q; Zhao KL; Fan M; Mao JF; Yang HJ; Wu KL; Fu XL
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):517-23. PubMed ID: 25481679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
    Colaco R; Sheikh H; Lorigan P; Blackhall F; Hulse P; Califano R; Ashcroft L; Taylor P; Thatcher N; Faivre-Finn C
    Lung Cancer; 2012 Apr; 76(1):72-7. PubMed ID: 22014897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
    Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J
    J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
    Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
    Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments].
    Yokoyama A; Kurita Y; Saijo N; Tamura T; Noda K; Shimokata K; Matsuda T
    Br J Cancer; 1998 Jul; 78(2):257-62. PubMed ID: 9683303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.